This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
International Agency for Research on Cancer. World Health Organization. Press release N. 263. [cited 2020 Feb 13]. Available at: https://www.who.int/cancer/PRGlobocanFinal.pdfInternational Agency for Research on Cancer. World Health OrganizationPress release N. 263. [cited 2020 Feb 13]. Available athttps://www.who.int/cancer/PRGlobocanFinal.pdfSearch in Google Scholar
Publications Office of the EU. Central and Eastern Europe. [cited 2020 Feb 14]. Available at: https://op.europa.eu/en/web/eu-vocabularies/th-concept/-/resource/eurovoc/914Publications Office of the EU. Central and Eastern Europe. [cited 2020 Feb 14]Available athttps://op.europa.eu/en/web/eu-vocabularies/th-concept/-/resource/eurovoc/914Search in Google Scholar
International Agency for Research on Cancer. World Health Organization. Lung cancer. [cited 2020 Feb 15]. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdfInternational Agency for Research on Cancer. World Health Organization. Lung cancer[cited 2020 Feb 15]. Available athttps://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdfSearch in Google Scholar
Huber RM, Ruysscher DD, Hoffmann H, Reu S, Tufman A. Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. Eur Respir Rev 2019; 28: 190024. doi: 10.1183/16000617.0024-2019HuberRMRuysscherDDHoffmannHReuSTufmanAInterdisciplinary multimodality management of stage III nonsmall cell lung cancerEur Respir Rev20192819002410.1183/16000617.0024-201931285288Open DOISearch in Google Scholar
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017; 151: 193-203. doi: 10.1016/j.chest.2016.10.010DetterbeckFCBoffaDJKimAWTanoueLTThe eighth edition lung cancer stage classificationChest201715119320310.1016/j.chest.2016.10.01027780786Open DOISearch in Google Scholar
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39-51. doi: 10.1016/j.jtho.2015.09.009GoldstrawPChanskyKCrowleyJRami-PortaRAsamuraHEberhardtWEEet alThe IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancerJ Thorac Oncol201611395110.1016/j.jtho.2015.09.00926762738Open DOISearch in Google Scholar
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1-21. doi: 10.1093/annonc/mdx222PostmusPEKerrKMOudkerkMSenanSWallerDAVansteenkisteJet alEarly and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201728iv1–2110.1093/annonc/mdx22228881918Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/NEJMoa1709937AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alDurvalumab after chemoradiotherapy in stage III non-small-cell lung cancerN Engl J Med201737719192910.1056/NEJMoa170993728885881Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379: 2342-50. doi: 10.1056/NEJMoa1809697AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCN Engl J Med201837923425010.1056/NEJMoa180969730280658Open DOISearch in Google Scholar
Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - update from PACIFIC. J Thorac Oncol 2020; 15: 288-93. doi: 10.1016/j.jtho.2019.10.002GrayJEVillegasADanielDVicenteDMurakamiSHuiRet alThree-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - update from PACIFICJ Thorac Oncol2020152889310.1016/j.jtho.2019.10.002724418731622733Open DOISearch in Google Scholar
McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm 2016; 38: 655-62. doi: 10.1007/s11096-016-0257-xMcMillanSSKingMTullyMPHow to use the nominal group and Delphi techniquesInt J Clin Pharm2016386556210.1007/s11096-016-0257-x490978926846316Open DOISearch in Google Scholar
Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, et al. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clin Transl Oncol 2019; 22: 759-71. doi: 10.1007/s12094-019-02191-yIslaDde CastroJGarcía-CampeloRLianesPFelipEGarridoPet alTreatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensusClin Transl Oncol2019227597110.1007/s12094-019-02191-y31368078Open DOISearch in Google Scholar
Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 2011; 13: 460-71. doi: 10.1007/s12094-011-0683-0IslaDGonzález-RojasNNievesDBrosaMFinnernHWTreatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panelClin Transl Oncol2011134607110.1007/s12094-011-0683-021775273Open DOISearch in Google Scholar
Darling G, Malthaner R, Dickie J, McKnight L, Nhan C, Hunter A, et al. Quality indicators for non-small cell lung cancer operations with use of a modified Delphi consensus process. Ann Thorac Surg 2014; 98: 183-90. doi: 10.1016/j.athoracsur.2014.03.001DarlingGMalthanerRDickieJMcKnightLNhanCHunterAet alQuality indicators for non-small cell lung cancer operations with use of a modified Delphi consensus processAnn Thorac Surg2014981839010.1016/j.athoracsur.2014.03.00124775804Open DOISearch in Google Scholar
Moldaver D, Hurry M, Evans WK, Cheema PK, Sangha R, Burkes R, et al. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer 2020; 139: 185-94. doi: 10.1016/j.lungcan.2019.10.019MoldaverDHurryMEvansWKCheemaPKSanghaRBurkesRet alDevelopment, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) modelLung Cancer20201391859410.1016/j.lungcan.2019.10.01931812889Open DOISearch in Google Scholar
Wang X, Su S, Li S, Bao H, Zhang M, Liu D, et al. Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China. BMC Cancer 2017; 17: 306. doi: 10.1186/s12885-017-3602-0WangXSuSLiSBaoHZhangMLiuDet alDevelopment of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in ChinaBMC Cancer20171730610.1186/s12885-017-3602-0557993628859609Open DOISearch in Google Scholar
Provencio M, Carcereny E, Artal Á. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Clin Transl Oncol 2019; 21: 1464-71. doi: 10.1007/s12094-019-02072-4ProvencioMCarcerenyEArtalÁConsensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancerClin Transl Oncol20192114647110.1007/s12094-019-02072-430903517Open DOISearch in Google Scholar
Milada Zemanová, Pirker R, Petruzelka L, Zbozínkova Z, Jovanovic D, Rajer M, et al. Care of patients with non-small-cell lung cancer Stage III – the Central European real-world experience. Radiol Oncol 2020; 54: 209-20. doi: 10.2478/raon-2020-0026MiladaZemanováPirkerRPetruzelkaLZbozínkovaZJovanovicDRajerMet alCare of patients with non-small-cell lung cancer Stage III – the Central European real-world experienceRadiol Oncol2020542092010.2478/raon-2020-0026727664832463394Open DOISearch in Google Scholar
Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, et al. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. J BUON 2007; 12: 33-9.RusuPCiuleanuTECerneaDPelauDGaalVCebotaruCet alConcurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II studyJ BUON200712339Search in Google Scholar
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Non-Small Cell Lung Cancer. Version 5.202, 27 May 2020. Avaiable at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Non-Small Cell Lung CancerVersion 5.202, 27 May2020Avaiable athttps://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfSearch in Google Scholar
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation | Guidance | NICE [Internet]. [cited 2020 Feb 27]. Available at: https://www.nice.org.uk/guidance/ta578/chapter/1-RecommendationsDurvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation | Guidance | NICE [Internet][cited 2020 Feb 27]. Available athttps://www.nice.org.uk/guidance/ta578/chapter/1-RecommendationsSearch in Google Scholar
Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol 2018; 52: 281-8. doi: 10.2478/raon-2018-0009VrankarMStanicKLong-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapyRadiol Oncol201852281810.2478/raon-2018-0009613736730210037Open DOISearch in Google Scholar
Ramlau R, Krawczyk P, Dziadziuszko R, Chmielewska I, Milanowski J, Olszewski W, et al. Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. Oncol Lett 2017; 14: 5611-8. doi: 10.3892/ol.2017.6907RamlauRKrawczykPDziadziuszkoRChmielewskaIMilanowskiJOlszewskiWet alPredictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in PolandOncol Lett2017145611810.3892/ol.2017.6907565603729113190Open DOISearch in Google Scholar
Podmaniczky E, Fábián K, Pápay J, Puskás R, Gyulai M, Furák J, et al. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer. Pathol Oncol Res 2015; 21: 423-31. doi: 10.1007/s12253-014-9839-xPodmaniczkyEFábiánKPápayJPuskásRGyulaiMFurákJet alDecreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung CancerPathol Oncol Res2015214233110.1007/s12253-014-9839-x25194563Open DOISearch in Google Scholar
Jeremić B. Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy. Clin Lung Cancer 2015; 16: 80-5. doi: 10.1016/j.cllc.2014.08.003JeremićB.Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapyClin Lung Cancer20151680510.1016/j.cllc.2014.08.00325450877Open DOISearch in Google Scholar
Georgieva N, Bochev P, Dancheva Z, Chaushev B, Balev B, Klisarova A, et al. PET/CT in NSCLC with brain metastases. Rentgenol Radiol 2014; 53: 204-10.GeorgievaNBochevPDanchevaZChaushevBBalevBKlisarovaAet alPET/CT in NSCLC with brain metastasesRentgenol Radiol20145320410Search in Google Scholar
Zielinski M, Szlubowski A, Kołodziej M, Orzechowski S, Laczynska E, Pankowski J, et al. Comparison of endobronchial ultrasound and/or endoesophageal ultrasound with transcervical extended mediastinal lymphadenectomy for staging and restaging of non-small-cell lung cancer. J Thorac Oncol 2013 ; 8: 630-6. doi: 10.1097/JTO.0b013e318287c0ceZielinskiMSzlubowskiAKołodziejMOrzechowskiSLaczynskaEPankowskiJet alComparison of endobronchial ultrasound and/or endoesophageal ultrasound with transcervical extended mediastinal lymphadenectomy for staging and restaging of non-small-cell lung cancerJ Thorac Oncol20138630610.1097/JTO.0b013e318287c0ce23584295Open DOISearch in Google Scholar
Kolodziejczyk M, Kepka L, Dziuk M, Zawadzka A, Szalus N, Gizewska A, et al. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2011; 80: 1008-14. doi: 10.1016/j.ijrobp.2010.04.018KolodziejczykMKepkaLDziukMZawadzkaASzalusNGizewskaAet alImpact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective studyInt J Radiat Oncol Biol Phys20118010081410.1016/j.ijrobp.2010.04.01820656419Open DOISearch in Google Scholar
Jeremić B, Miličić B, Milisavljevic S. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients. Clin Transl Oncol 2012; 14: 613-8. doi: 10.1007/s12094-012-0848-5JeremićBMiličićBMilisavljevicSToxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patientsClin Transl Oncol201214613810.1007/s12094-012-0848-522855143Open DOISearch in Google Scholar
Kepka L, Bujko K, Orlowski TM, Jagiello R, Salata A, Matecka-Nowak M, et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. Radiother Oncol 2011; 98: 238-43. doi: 10.1016/j.radonc.2010.09.020KepkaLBujkoKOrlowskiTMJagielloRSalataAMatecka-NowakMet alCardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapyRadiother Oncol2011982384310.1016/j.radonc.2010.09.02020951453Open DOISearch in Google Scholar
